Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ndjeka

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Ebiomedicine|January 17, 2018
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort StudyNazir A Ismail, Shaheed V Omar, Lavania Joseph, et al.
Frontiers in Public Health|April 8, 2026
Missed PrEP opportunities and vulnerability to HIV during rifampicin-resistant tuberculosis treatment in South AfricaAdam Leonard, Kelly Lowensen, Elizabeth Di Giacomo, et al.
The Lancet. Infectious Diseases|March 25, 2024
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experienceKogieleum Naidoo, Rubeshan Perumal, Helen Cox, et al.
The Lancet. Global Health|March 19, 2026
Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018-22: an observational cohort studySuzette Oelofse, Aliasgar Esmail, Tahlia Perumal, et al.
The Lancet. Respiratory Medicine|July 14, 2018
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyKathryn Schnippel, Norbert Ndjeka, Gary Maartens, et al.
Vaccine|May 26, 2026
Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshopNorbert Ndjeka, Priashni Subrayen, Willem A Hanekom, et al.
Plos One|August 8, 2017
Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant tuberculosis in South AfricaJason E Farley, Norbert Ndjeka, Ana M Kelly, et al.
The Lancet. Microbe|August 3, 2023
Diagnostics to support the scaling up of shorter, safer tuberculosis regimensDavid Branigan, Claudia M Denkinger, Jennifer Furin, et al.
The New England Journal of Medicine|June 24, 2026
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant TuberculosisFrancesca Conradie, Tasnim Badat, Asanda Poswa, et al.
Plos One|October 21, 2024
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysisDenise Evans, Kamban Hirasen, Clive Ramushu, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Ebiomedicine|January 17, 2018
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort StudyNazir A Ismail, Shaheed V Omar, Lavania Joseph, et al.
Frontiers in Public Health|April 8, 2026
Missed PrEP opportunities and vulnerability to HIV during rifampicin-resistant tuberculosis treatment in South AfricaAdam Leonard, Kelly Lowensen, Elizabeth Di Giacomo, et al.
The Lancet. Infectious Diseases|March 25, 2024
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experienceKogieleum Naidoo, Rubeshan Perumal, Helen Cox, et al.
The Lancet. Global Health|March 19, 2026
Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018-22: an observational cohort studySuzette Oelofse, Aliasgar Esmail, Tahlia Perumal, et al.
The Lancet. Respiratory Medicine|July 14, 2018
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyKathryn Schnippel, Norbert Ndjeka, Gary Maartens, et al.
Vaccine|May 26, 2026
Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshopNorbert Ndjeka, Priashni Subrayen, Willem A Hanekom, et al.
Plos One|August 8, 2017
Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant tuberculosis in South AfricaJason E Farley, Norbert Ndjeka, Ana M Kelly, et al.
The Lancet. Microbe|August 3, 2023
Diagnostics to support the scaling up of shorter, safer tuberculosis regimensDavid Branigan, Claudia M Denkinger, Jennifer Furin, et al.
The New England Journal of Medicine|June 24, 2026
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant TuberculosisFrancesca Conradie, Tasnim Badat, Asanda Poswa, et al.
Plos One|October 21, 2024
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysisDenise Evans, Kamban Hirasen, Clive Ramushu, et al.
Pageof 6